Skip to NavigationSkip to content

IAVI

GSK's tuberculosis vaccine shows efficacy over three years in HIV negative patients

Promising results have been revealed from a GlaxoSmithKline study, conducted in partnership with non-profit scientific research organisation IAVI, investigating the efficacy of the company’s M72/AS01E tuberculosis (TB) vaccine in HIV-negative adults with latent TB infection.

The study was conducted across 11 sites throughout Kenya, South Africa and Zambia – all TB-endemic regions – enrolling 3,573 HIV-negative participants between 18 and 50 years old.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches